Christie + Co
HealthInvestor Awards 2015 Finalists
Remember me:
Skip Navigation Links
Axis-Shield resists new Alere takeover attempt

UK-based diagnostics company Axis-Shield has urged shareholders to resist a fresh takeover attempt by US rival Alere.

In a statement today, Alere repeated its offer to Axis-Shield’s shareholders of 460 pence per share, which was formally made on 5 August. The offer, rejected by the Axis-Shield board, values the business at £230 million.

Alere announced today that it is lowering the threshold of its bid, which had been set at 90% of shareholder acceptance. The company said it now required more than 50% of voting rights, giving it the option of becoming a majority shareholder in Axis-Shield.

The US company also warned that if its offer were to lapse by a deadline of 10 October, “there is a strong possibility that Axis-Shield's share price would fall significantly below its current share price, particularly as no other potential bidder has announced its interest publicly”.

Alere said it was also looking at “alternative acquisitions, particularly in light of current valuations and market conditions”, and that it didn’t necessarily have to acquire Axis-Shield in order to achieve its “strategic objectives”.

In response, Axis-Shield’s board said it was “disappointed” that Alere had not taken notice of the “firm rebuttal” from shareholders to its offer, which it said was clear by the less than 1% level of acceptances that was disclosed in an Alere announcement on 16 September.

“The board has been more than willing to engage with Alere if Alere were to put a proposal to the board that fairly reflected the fundamental value of Axis-Shield. To date, no such proposal has been received from Alere,” said an Axis-Shield statement.

“The company has made excellent progress in the first half of the year and is on track to deliver for the second half of the year. The company believes that Alere is making a highly opportunistic offer in order to try and acquire Axis-Shield on the cheap.”

The 460 pence per share offer price represents a premium of 37% on the closing share price of 335 pence on 5 July 2011 – the last business day before Alere revealed it was considering an approach.

Posted on: 26/09/2011

Latest news stories

The Court of Appeal has rejected HCA International’s case for a different Competition & Markets Authority team to reassess whether it should divest some of its facilities.
A consortium led by Prime has been selected to deliver 14 primary care centres across Ireland, a project with a combined capital value of €140 million (£101.4 million).
Outsourcing firm Mitie has reported a 61.4% decrease in operating profit for its health division, which comprises of domiciliary care business MiHomecare and Complete Group.
Prime Minister David Cameron has repeated his vow to boost NHS funding and to create a “seven-day health service”.
Private healthcare provider Care UK has sold its learning disabilities division to Lifeways for an undisclosed sum.

HealthInvestor Asia - financial intelligence for Asia's healthcare markets

The children’s care and education market is in need of a good news story. Acorn chief executive Natalie-Jane Macdonald tells Ploy Radford about her plans to achieve just that
The furrier end of the healthcare market has dynamics those with stakes in human care would be jealous of, finds Ploy Radford, but which part of it should investors pursue?
Former Four Seasons’ boss Pete Calveley has moved from one care home giant to another, and now, he tells Ploy Radford, he plans to turn Barchester Healthcare into a sector titan

Christie + Co
Sunniva Davies-Rommetveit explores whether there has been enough focus on Simon Stevens’ 29 vanguard sites, or whether the political discourse has been overly focused on NHS finances
Technology has long been hailed as the panacea for what ails healthcare, but take-up of available solutions continues to disappoint, argues Kirsten Noben
The general election is nearly here but what key election issues will still be around regardless of who wins? Candesic’s Dr Michelle Tempest discusses the ramifications for health and social care
The Pennine Acute NHS Trust is combating A&E queues by teaming up with LloydsPharmacy. The trust’s clinical director of urgent care, Dr Jimmy Stuart, discusses the ins and outs of the deal
Clare Connell and Hannah Hurley of Connell Consulting discuss the challenges of treating for dual diagnosis service users

Click here to search all feature articles